The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection

Cancer Communications

Table 1 Comparison of characteristics between two groups of biliary tract cancer (BTC) patients undergoing microscopically margin-negative (R0) resection

Characteristic	Adjuvant chemotherapy (n = 89)	Observation (n = 64)	P value
Age (years) ^a			0.072
Median (range)	64 (36–83)	67 (47–80)
Gender			0.048
Male	50 (56.2)	46 (71.9)
Female	39 (43.8)	18 (28.1)
Tumor location			0.480
Gallbladder	43 (48.3)	34 (53.1)
Intrahepatic bile duct	33 (37.1)	18 (28.1)
Perihilar bile duct	3 (3.4)	5 (7.8)
Distal bile duct	10 (11.2)	7 (10.9)
Histologic differentiation			0.225
Well	34 (38.2)	25 (39.1)
Moderate	31 (34.8)	30 (46.9)
Poor	17 (19.1)	7 (10.9)
Unspecified^b	7 (7.9)	2 (3.1)
AJCC stage			0.152
I	26 (29.2)	29 (45.3)
II	35 (39.3)	20 (31.2)
III	18 (20.2)	12 (18.8)
IVA^c	10 (11.2)	3 (4.7)
Lymph node involvement			0.426
Yes	23 (25.8)	13 (20.3)
No	66 (74.2)	51 (79.7)
CA 19-9 (U/mL) (n = 126) ^{a, d}			0.328
Median (range)	25.3 (0.1–11,150.0)	17.6 (0.6–9700.0)

AJCC American Joint Committee on Cancer (7th edition), CA 19-9 carbohydrate antigen 19-9
^aExcept these, other values are presented as number of patients with percentage in parentheses
^bIncludes undifferentiated carcinoma (n = 3), signet ring cell carcinoma (n = 2), carcinosarcoma (n = 2), pleomorphic carcinoma (n = 1), and large cell neuroendocrine carcinoma (n = 1)
^cAll patients had intrahepatic bile duct cancers; 12 patients had TxN1M0 disease and 1 had T4N0M0 disease
^dBaseline CA 19-9 levels were available for 77 patients in the adjuvant chemotherapy group and 49 patients in the observation group

ISSN: 2523-3548